John J. Miller, MD

"There is clearly a large unmet need not only to improve our treatment of AD, but to provide treatment options for all the dementias."

Should cannabis be regulated in the United States in a manner similar to alcohol and tobacco?

An inside look at what treatments are being discussed in San Francisco...

"It is essential to have an aggressive path forward to increase public awareness of mental health and illness, education on early intervention and treatment access, and continued destigmatization of mental illness."

Patients' symptoms often have an etiology that is actually "all in their head..."

A look at one of the most informative yet easy-to-administer tests for assessing brain dysfunction.

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

Remember to keep the cart behind the horse while practicing medicine.

We remain challenged to improve treatments and outcomes in schizophrenia. Explore the latest options.

What is most memorable about your childhood holiday celebrations?

What happened in 1922, and how do these events look 100 years later?

"The cog in the wheel of treatment today is misinformation and lack of trust in the institutions of medicine, peer-reviewed published literature, the CDC, and pharmaceutical research."

"As clinicians who took an oath to 'do no harm,' we must educate the public about the dangers and non–standard of care of the growing practice of at-home ketamine."

Missing out on treating a person rather than a diagnosis?

"It would be naïve to believe that targeting a single neurotransmitter, receptor, or circuit in the brain will cure any psychiatric or neurological disorder. However, we would be remiss if we did not try."

These are the extra figures for John J. Miller, MD's article, "Serotonin: A Biography" from the 2022 September issue.

CBD and THC? What's the difference and why does it matter?

The resistance against "magic mushrooms"—is it justified?

Here's why more research is important to help us better understand the effects of cannabis on our patients.

Is the term, "extrapyramidal symptoms," an example of a “4-letter word”?

"The young and exciting field of psychiatric pharmacogenomics is providing a third pillar of understanding to aid in our competent and informed prescribing of drugs, joining the more well-established pillars of pharmacokinetics and pharmacodynamics."

What does the Psychiatric Times Editor in Chief think about 988?

What are the benefits of early and comprehensive intervention for patients in their first episode of a serious mental illness?

Our Editor in Chief is thrilled to be live and in person at the 2022 APA Annual Meeting in New Orleans. Here's why.

How do social stressors contribute to patient symptoms?

There have been many exciting advances in telemedicine in recent years. But does telemedicine really allow us to be genuinely present for our patients?

The 2022 Annual Psychiatric Times World CME Conference is coming in August.

Take a look at the 4 primary movement disorders commonnly encountered in psychiatry when antipsychotics are prescribed.

How can you empower the patient to be part of the discussion surrounding their treatment?